- $1.95bn
- $1.72bn
- $1.17bn
- 92
- 48
- 93
- 93
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 32.92 | ||
| PEG Ratio (f) | 2.08 | ||
| EPS Growth (f) | 18.83% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.62 | ||
| Price to Tang. Book | 4.81 | ||
| Price to Free Cashflow | 11.23 | ||
| Price to Sales | 1.67 | ||
| EV to EBITDA | 24.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.38% | ||
| Return on Equity | 11.14% | ||
| Operating Margin | 5.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 344.86 | 500.62 | 786.91 | 1,088.6 | 1,167.22 | 1,209.95 | 1,347.62 | 38.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +22.25 | -53.66 | +102.9 | -6.07 | +1.58 | +55.27 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Directors
- David Schlanger CHM (61)
- Michael Sturmer PRE (45)
- Peter Anevski CEO (54)
- Mark Livingston CFO (55)
- Jennifer Bealer EVP (40)
- Beth Seidenberg LED (64)
- Malissia Clinton IND (52)
- Frederick Cohen IND (64)
- Kevin Gordon IND (58)
- Roger Holstein IND (69)
- Jeffrey Park IND (49)
- Norman Payson IND (72)
- Cheryl Scott IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 3rd, 2008
- Public Since
- October 25th, 2019
- No. of Shareholders
- 42
- No. of Employees
- 675
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 85,668,392
- Address
- 1359 Broadway, NEW YORK, 10018
- Web
- https://www.progyny.com/
- Phone
- +1 2128883124
- Auditors
- Ernst & Young LLP
Upcoming Events for PGNY
Q1 2025 Progyny Inc Earnings Call
Progyny Inc Annual Shareholders Meeting
Progyny Inc Annual Shareholders Meeting
Q2 2025 Progyny Inc Earnings Release
Similar to PGNY
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
FAQ
What is the Progyny share price?
As of Today at 04:44 UTC, shares in Progyny are trading at $22.76. This share price information is delayed by 15 minutes.
How has the Progyny share price performed this year?
Shares in Progyny last closed at $22.76 and the price had moved by -29.97% over the past 365 days. In terms of relative price strength the Progyny share price has underperformed the S&P500 Index by -35.36% over the past year.
What are the analyst and broker recommendations for Progyny?
The overall consensus recommendation for Progyny is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Progyny dividend yield?
Progyny does not currently pay a dividend.
Does Progyny pay a dividend?
Progyny does not currently pay a dividend.
When does Progyny next pay dividends?
Progyny does not currently pay a dividend.
How do I buy Progyny shares?
To buy shares in Progyny you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Progyny?
As of the previous close price of $22.76, shares in Progyny had a market capitalisation of $1.95bn.
Where are Progyny shares listed?
Here are the trading details for Progyny:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PGNY
What kind of share is Progyny?
Based on an overall assessment of its quality, value and momentum Progyny is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Progyny share price forecast for 2025?
The analyst consensus target price for shares in Progyny is $27.29. That is 19.9% above the last closing price of $22.76.
Analysts covering Progyny currently have a consensus Earnings Per Share (EPS) forecast of $0.59 for the next financial year.
Find out moreWhat is the trend in the Progyny share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Progyny. Over the past six months, its share price has outperformed the S&P500 Index by +55.27%.
As of the last closing price of $22.76, shares in Progyny were trading +12.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Progyny PE Ratio?
The Progyny PE ratio based on its reported earnings over the past 12 months is 32.92. The shares last closed at $22.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Progyny?
Progyny's management team is headed by:
- David Schlanger - CHM
- Michael Sturmer - PRE
- Peter Anevski - CEO
- Mark Livingston - CFO
- Jennifer Bealer - EVP
- Beth Seidenberg - LED
- Malissia Clinton - IND
- Frederick Cohen - IND
- Kevin Gordon - IND
- Roger Holstein - IND
- Jeffrey Park - IND
- Norman Payson - IND
- Cheryl Scott - IND